Memento Medicines closed a $93M Series A for MMT-205, a bispecific antibody that activates Tie2 and inhibits VEGF simultaneously — targeting the largest unmet gaps in nAMD and DME treatment.
In June 2026, Reed Semiconductor closed a $100 million funding round backed by several leading global semiconductor companies. The round was oversubscribed. Investors wanted in faster than Reed could allocate. The company builds power management chips for AI data centers from its headquarters in Warwick, Rhode Island. This is the
$75 million. Oversubscribed. For a platform most biotech investors haven't heard of — yet. Lycia Therapeutics, a South San Francisco biotech built on Nobel Prize-winning chemistry, closed its Series D on June 25. The round was co-led by Janus Henderson and Balyasny Asset Management, with participation from
A&K Robotics raises $8M Series A to scale Cruz autonomous pods at Vancouver and Madrid airports. The company's crowd-aware Kinesos AI tackles indoor mobility where road AVs don't go.
Omni Analytics raised $120M Series C at $1.5B valuation. The ex-Looker team's semantic layer bet: making enterprise AI data trustworthy.
London biotech RQ Bio raised $115M for RQB01, a long-acting antibody aiming to replace annual flu shots for high-risk patients.
Baseten tripled ARR to $600M in one quarter, raised $1.5B at $13B. The inference infrastructure market has arrived.
IN-SPACe selects Astrobase, SatSure and TM2SPACE as first beneficiaries of ₹500 crore Technology Adoption Fund — covering propulsion, Earth observation AI, and satellite navigation
Robotics venture funding hit $23B in the first half of 2026, matching all of 2025. Here is where the money is going — by company, category, and geography.
In June 2026, Reed Semiconductor closed a $100 million funding round backed by several leading global semiconductor companies. The round was oversubscribed. Investors wanted in faster than Reed could allocate. The company builds power management chips for AI data centers from its headquarters in Warwick, Rhode Island. This is the
Omni Analytics raised $120M Series C at $1.5B valuation. The ex-Looker team's semantic layer bet: making enterprise AI data trustworthy.
Baseten tripled ARR to $600M in one quarter, raised $1.5B at $13B. The inference infrastructure market has arrived.
Golden Analytics raised $14M seed extension led by Insight Partners, totaling $21M. Nearly 1,000 companies requested early access to its AI-native analytics platform with a 'slider of autonomy' that lets users control how much AI drives their workflow.
$75 million. Oversubscribed. For a platform most biotech investors haven't heard of — yet. Lycia Therapeutics, a South San Francisco biotech built on Nobel Prize-winning chemistry, closed its Series D on June 25. The round was co-led by Janus Henderson and Balyasny Asset Management, with participation from
London biotech RQ Bio raised $115M for RQB01, a long-acting antibody aiming to replace annual flu shots for high-risk patients.
The global clinical pipeline contains over 22,000 active compounds. Yet 90% of candidates fail. AI, regulatory reform, and new modalities are reshaping how drugs go from target discovery to commercial launch.
The WEF's 3C framework — combination, convergence, compounding — explains why the winners in tech are no longer the most advanced, but the most ready to integrate.
A&K Robotics raises $8M Series A to scale Cruz autonomous pods at Vancouver and Madrid airports. The company's crowd-aware Kinesos AI tackles indoor mobility where road AVs don't go.
Robotics venture funding hit $23B in the first half of 2026, matching all of 2025. Here is where the money is going — by company, category, and geography.
Ex-Waymo engineers raised $270M to retrofit excavators and bulldozers with autonomy — turning construction equipment into machines that work without operators.
The WEF's 3C framework — combination, convergence, compounding — explains why the winners in tech are no longer the most advanced, but the most ready to integrate.